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Objective—To assess neurocognitive outcomes following antipsychotic intervention in youth
enrolled in the National Institute of Mental Health (NIMH)-funded Treatment of Early-Onset
Schizophrenia Spectrum Disorders (TEOSS).
Method—Neurocognitive functioning of youth (ages 8–19 years) with schizophrenia or
schizoaffective disorder was evaluated in a four-site randomized, double-blind clinical trial
comparing molindone, olanzapine or risperidone. The primary outcomes were overall group
change from baseline in neurocognitive composite and six domain scores after 8 weeks and
continued treatment up to 52 weeks. Age and sex were included as covariates in all analyses.
Results—Seventy-seven of 116 TEOSS participants (66%) had post-baseline neurocognitive
data. No significant differences emerged in the neurocognitive outcomes of the three medication
groups. Therefore, the three treatment groups were combined into one group to assess overall
neurocognitive outcomes. Significant modest improvements were observed in the composite score
and in three of six domain scores in the acute phase, and in four of six domain scores in the
combined acute and maintenance phases. Partial correlation analyses revealed very few
relationships among Positive and Negative Syndrome Scale (PANSS) baseline or change scores
and neurocognition change scores.
Conclusions—Antipsychotic intervention in youth with early-onset schizophrenia spectrum
disorders (EOSS) led to modest improvement in measures of neurocognitive function. The
changes in cognition were largely unrelated to baseline symptoms or symptom change. Small
treatment effect sizes, easily accounted for by practice effects, highlight the critical need for the
development of more efficacious interventions for the enduring neurocognitive deficits seen in
EOSS.
Keywords
early-onset; schizophrenia; neurocognition; outcomes; antipsychotics
INTRODUCTION
Early-onset schizophrenia (EOS) is defined by having the onset of symptoms prior to age
18. The lifetime prevalence of schizophrenia is 1%, with a substantial number of individuals
diagnosed prior to age 18.1, 2 EOS is often more severe than adult-onset schizophrenia
(AOS) and includes both a higher rate of premorbid abnormalities and worse functional
outcome.3–5 Studies have documented comparable neurocognitive deficits in EOS and
AOS,6, 7 including a recent meta-analysis that showed mostly large deficits for EOS
compared to controls [effect sizes ranged from −1.27 (processing speed) to −0.58 (motor
skills)].8 Another meta-analysis documented more severe neurocognitive deficits in EOS
compared with AOS,9 suggesting that illness severity may be associated with age of onset.10
The adult literature demonstrates that neurocognitive deficits are stronger predictors of
social and role functioning than other illness features.11, 12 Similarly, a recent 13-year
follow-up study of EOS found that baseline neurocognitive measures were associated with
social and community functioning at follow-up.13
Neurocognitive functioning is an important target of treatment.14 Much of the earlier
research on antipsychotics in adults with schizophrenia suggested favorable cognitive
enhancing effects of second-generation antipsychotics (SGAs) over first-generation
antipsychotics (FGAs).15 Data from the NIMH-sponsored Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE)16 and the European First Episode Schizophrenia Trial
(EUFEST) randomized clinical trials,17 however, failed to support the early claims of SGA
superiority. Both CATIE and EUFEST interpreted their lack of differential medication
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effects as being due, in part, to the administration of FGAs at lower and more appropriate
doses. The effects of antipsychotics in youth with EOSS disorders are just beginning to be
understood. Controlled efficacy studies18–23 have documented that antipsychotics are
superior to placebo in reducing positive and negative symptoms, but there have been no
studies of antipsychotic effects on cognition in youth with EOSS.
The NIMH-funded multisite randomized controlled trial “Treatment of Early-Onset
Schizophrenia Spectrum Disorders (TEOSS)” provided an opportunity to examine this issue
in the largest sample of youths with EOSS studied to date.4, 24 The initial purpose of this
study was to compare the effects of olanzapine, risperidone, and molindone on
neurocognition. However, due to limited power, the main focus of this paper is on whole
group analyses to evaluate neurocognitive outcomes following antipsychotic treatment. We
expected that the overall group would demonstrate modest improvements in neurocognition
with antipsychotic treatment as evidenced by change in a single composite score and, to a
lesser degree, change in specific domain scores at 8 weeks and 52 weeks or termination. We
also assessed relationships among baseline and changes in clinical symptoms and change in
the neurocognitive composite and domain scores.
METHOD
Study Design
The TEOSS study design, methods and results have been described previously.20, 22, 24
TEOSS participants were randomized to one of three active treatments (risperidone,
olanzapine or molindone). In this report, we focus on treatment-related change in
neurocognition from baseline to weeks 8 and 52/termination, and between weeks 8 and 52/
termination. Neurocognitive assessments were administered at baseline and the end of the
acute phase (week 8). After acute treatment (week 8), participants who had adequate
response (20% decrease in baseline Positive and Negative Syndrome Scale [PANSS]25 score
plus a Clinical Global Impression-Improvement [CGI-I]26 score of ≤ 2) and tolerated their
randomized treatment, were eligible to begin maintenance phase treatment with the same
antipsychotic medication under double-blind conditions. Individuals who did not have
adequate response at week 8, or relapsed or experienced intolerable adverse effects during
either the acute or maintenance phase, were offered randomly assigned, double-blind
treatment with one of the other study medications for up to 52 weeks of treatment.20 The
data reported here are based on changes observed during treatment with whichever
medication was used for the longest period. The maintenance phase was up to a total of 44
weeks and the TEOSS neurocognitive battery was administered a third time at the end of the
maintenance phase or at study termination. Neurocognitive assessments were obtained at
week 8 and 52/termination during all subsequent treatments.
Participants
TEOSS enrolled youths (age 8 to 19 years) meeting DSM-IV diagnostic criteria for
schizophrenia, schizoaffective disorder or schizophreniform disorder.27 Diagnoses were
confirmed with the Structured Clinical Interview for DSM-IV Childhood Diagnoses (KID-
SCID).28 Participants also had to have a score of moderate or greater on at least one PANSS
positive symptom item.29 Additional details regarding methods and baseline sample
characteristics are described elsewhere.4, 7, 22, 24
Neurocognitive Measures
The battery of tasks assessed the following neurocognitive domains: general intellectual
functioning [Wechsler Abbreviated Scale of Intelligence (WASI)30]; Academic achievement
skills [Wide Range Achievement Test (WRAT-3)31 Reading, Spelling and Arithmetic
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subtests]; Fine-motor speed and coordination [Finger Tapping Test (FT),32 Grooved
Pegboard (GP)33]; Attention and inhibitory control [auditory and visual versions of VIGIL
Continuous Performance Test (CPT)34]; Short-Term Memory [Hopkins Verbal Learning
Test-Revised (HVLT-R),35 Wide Range Assessment of Memory and Learning (WRAML)36
Visual Learning subtest, Visuospatial Working Memory Test (VSWM),37 Woodcock-
Johnson-III (WJ-III) Numbers Reversed38 ]; Cognitive Efficiency [Controlled Oral Word
Association Test (COWAT),39 Ruff Figural Fluency Test (RFFT),40]; and Social Cognition
[Eyes Test41]. The WASI, WRAT-3, and Wisconsin Card Sorting Test-64-Computer
Version (WCST-64-CV)42 were administered at baseline and termination only; all other
measures were administered at each time point. Cognitive measures were selected based on
their established psychometric properties, potential sensitivity to medication treatment, and
general alignment with CATIE.16
Data Analysis
Neurocognitive Dataset Construction—The baseline neurocognitive data always
came from the week a patient entered TEOSS (week zero). That is, baseline data remained
constant, regardless of re-randomization in order to insure a uniform starting point (i.e.,
study entry) for all subjects. In contrast, post-baseline data points varied to some extent
across subjects. To minimize practice effects, all data from a post-baseline (e.g., “week 8”)
neurocognitive visit were excluded if the visit occurred less than six weeks after the
previous visit. Data included for the week 8 and termination assessments came from weeks 6
through 10 and 16 through 52, respectively. Some patients had post-baseline neurocognitive
data from more than one medication randomization. To maximize sample size, data from all
available randomizations were considered, but each patient only contributed one set of post-
baseline scores to the analyses. For example, if the first randomization included both week 8
and termination data then the first randomization would be included. In general, the
randomization that had the most post-baseline data was selected for inclusion in the post-
baseline analysis. A later randomization was included instead of an earlier one if the latter
had both week 8 and termination data and the earlier randomization had only week 8 data or
only termination data. In all cases, regardless of which randomization was chosen for
inclusion in the post-baseline data set, the baseline data was always from week 0.
Data Reduction: Neurocognitive Domain and Composite Scores
Given that most single neuropsychological measures are moderately intercorrelated,43, 44 we
chose to reduce the number of variables for analysis by constructing domain and composite
score measures, a strategy commonly employed in clinical trials.16 Such summary measures
are also often more sensitive to treatment effects than single test scores, and composite
measures are often more reliable and sensitive than domain scores.45 Construction of
domain scores was rationally derived and consistent with our earlier work.7 Each individual
test measure was evaluated for normality and outliers to support subsequent data reduction.
Single test measures were first converted to standardized z-scores by subtracting the
baseline mean and dividing by the baseline standard deviation based on the sample
contributing to the analysis of each test measure. Such standardization using baseline scores
was performed to produce three sets of standardized single test measures, one for each of the
groups of subjects contributing to the baseline to 8 weeks, 8 weeks to 52 weeks, and
baseline to 52 weeks analyses of each test measure. Domain summary scores were then
constructed by calculating the mean of the z-scores for the measures that comprised the
domain, and then re-standardizing the domains using baseline data as described previously.
This re-standardization was employed so that baseline data for each of the three time point
analyses of each domain had a mean of 0 and a standard deviation of 1, enabling post-
baseline means to be interpreted as effect sizes. This process resulted in six domain scores as
follows: Fine Motor Speed/Coordination; Attention; Short-Term Memory; Cognitive
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Efficiency; Inhibitory Control (auditory and visual Vigil CPT commission errors); and
Social Cognition. Additionally, composite scores for Academic Achievement and full-scale
IQ were constructed in a similar way. See Table 1 for a list of neurocognitive assessments
included in each domain and composite.
An overall neurocognitive composite score was calculated as an unweighted average of the
six domain summary scores: Fine Motor Speed/Coordination, Attention, Short-Term
Memory, Cognitive Efficiency, Inhibitory Control, and Social Cognition. After averaging
the six domain summary scores, the composite score was re-standardized using baseline data
as described earlier, so that post-baseline means could be interpreted as effect sizes. A
composite score was computed only for those subjects with available data on at least 4 of 6
of the domains (n=70). Full scale IQ and Academic Achievement summary scores were
computed for baseline and week 52/termination and were not available for week 8 per the
study design. They did not contribute to the neurocognitive composite score and are treated
as composite scores themselves in the analysis. This resulted in a total of six domain and
three composite scores for subsequent analyses. Note that data from the WCST-64-CV was
not included in these analyses as data was only available for baseline and 52 week/
termination time points per the study design, and the goal of this study was to examine
change across three time points (baseline, 8-week/acute phase, and 52-week/termination); as
a result, the problem-solving efficiency domain name that we used in our baseline
neurocognitive paper7 was changed to cognitive efficiency here to better reflect the
constituent measures of the domain. Four (multi-measure) domain reliability coefficients
were acceptable (i.e., Cronbach alpha reliability coefficients ranged between 0.78 and 0.80);
however, the internal consistency of the Problem-Solving Efficiency domain was 0.64.
Statistical Methods
Descriptive statistics for all neurocognitive domain and composite scores were examined for
normality and outliers. Change in each standardized neurocognitive domain and composite
score from baseline to week 8 or termination/endpoint was compared using multiple analysis
of covariance (ANCOVA), adjusting for baseline score, age and sex. For clarity and
consistency in interpreting the results, age and sex were included as covariates in all models
regardless of whether either was a significant predictor in the model. Given multiple
comparisons, a Bonferroni correction would establish conservative critical values of p <
0.008 for the six neurocognitive domain variables (0.05/6) and p < 0.017 for the
neurocognitive composite, IQ, and academic achievement summary scores (0.05/3).
Standardized mean change scores provide an effect size estimate that indexes the magnitude
of the difference in cognitive domain performance level between time points; positive
standardized mean change scores indicate performance improvement, while negative values
suggest reduced performance. In order to assess whether there was any greater or lesser
cognitive improvement in the younger children versus the older children, we inspected
whether age was a significant predictor in the model for each neurocognitive outcome and
time point comparison. To correct for the analysis of multiple outcomes, the same
Bonferroni p-value corrections were applied to the hypothesis tests determining significance
of age in each model. Lastly, partial correlation analyses (adjusted for age and sex) were
conducted to examine relationships among PANSS (Total, Positive, and Negative scale)
baseline and change scores and neurocognitive domain and composite change scores.
Significance levels for the correlation analyses were set at p < 0.008 for the six domain
composite scores and p < 0.017 for the three other composite scores. Analyses were
conducted using SAS 9.2.
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Subjects and Baseline Characteristics
Of the 116 participants treated in TEOSS, 77 (66%) had post-baseline neurocognitive data
suitable for analysis (see Figure 1). Table 2 shows baseline demographic and clinical
characteristics of the sample with post-baseline neurocognitive data and those without. The
sample was 2/3 male and, on average, 14.3±2.5 years old. Youth included in these analyses
did not differ significantly from the non-neurocognitive sample (those without baseline or
post-baseline neurocognitive data; n=39) on most variables. However, the neurocognitive
sample was more symptomatic at baseline than the non-neurocognitive sample, having
higher PANSS-Total, PANSS-Negative, and BPRS-C Total Scores. Because baseline
neurocognitive data was often not available for the non-neurocognitive sub-sample, Table 2
does not provide group comparative baseline neurocognitive data.
Neurocognitive Effects of Treatment
There were no significant differences among the three medication groups on any
neurocognitive change variable at any time point. Given limited statistical power, the groups
were combined to focus on change in neurocognition for the overall group. Table 3 presents
the means and standard deviations for the neurocognitive variables at each assessment point,
and their related mean standardized change score (and standard deviation) around which
these results are organized. Note that sample sizes vary across neurocognitive variables
based on available data, and are reduced when comparisons are made with the 52-week/
termination assessment point. Change in the neurocognitive composite score, the primary
outcome measure, showed significant improvement during acute and combined acute and
maintenance treatment. Compared to their study entry baseline performance, participants’
neurocognitive composite showed modest improvement by week 8 (z = 0.27, p < .0001) and
improvement at 52-weeks/termination (z = 0.31, p = 0.0005). Significant differences were
not observed on the composite score between the 8-week and 52-week/termination
assessments.
Significant change was seen in three of six neurocognitive domains between baseline and
week 8 and four of six domains between baseline and week 52/termination (see Table 2).
Significant improvements were shown in Fine motor speed/coordination at 8-weeks (z =
0.21, p = 0.0016) and 52-weeks/termination (z = 0.27, p = 0.006). Inhibitory Control also
showed significant improvements at both time points (z = 0.25, p < 0.0001; z = 0.25, p =
0.0007, respectively). Significant improvements were documented in Social Cognition
between baseline and 8-weeks (z = 0.28, p = 0.0072) only, and in Attention (z = 0.16, p =
0.0048) and Cognitive Efficiency (z = 0.28, p = 0.0008) between baseline and 52-weeks/
termination only. One neurocognitive domain, Cognitive Efficiency, demonstrated
improvement over the 8 to 52 weeks maintenance phase (z = 0.18, p = 0.013). Notably, no
significant changes were observed in the Short-Term Memory domain at any follow-up
assessment point. All effect sizes were small to very small.
In the analysis of age as predictor in the model for each neurocognitive outcome and time
point comparison, only the model for change in Attention between weeks 8 and termination
was significant, indicating that older children showed greater improvement in attention than
younger children (coefficient for the age predictor = 0.132; p=0.0007). No other significant
differential age effects were found.
As expected, there was no significant change observed in the WASI Full Scale IQ (z = 0.06,
p = 0.33) or in the Academic Achievement composite score based on the WRAT-3 subtests
(z = −0.04, p = 0.51).
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Neurocognitive Change and Baseline Symptom Severity and Symptom
Change—Partial Pearson correlations (adjusting for age and sex) between change in
neurocognitive composite and domain scores from baseline and clinical symptom severity at
baseline and change in PANSS total score and symptom factors were calculated to examine
their associations. Using criteria for significance of p = 0.008 for the domains and 0.017 for
the composites, few significant relationships emerged. The correlation between change in
PANSS Total and change in Attention from 8 to 52 weeks was significant (r = 0.41, p =
0.006) and the correlation between baseline PANSS Negative and change in Fine Motor
Speed from week 8 to 52 was significant (r = −0.38, p = 0.007). These data suggest little
reliable relationship between baseline levels of symptoms or their change over time and
change in any neurocognitive index.
DISCUSSION
This is the first study of EOS to prospectively assess neurocognitive functioning in a large,
well-characterized sample of youth over the course of a 52-week double-blind treatment trial
with antipsychotic medication. We found that neurocognition, as indexed by a
neurocognitive composite score, improved modestly with antipsychotic treatment between
study entry and 8- and 52-weeks, with the largest proportion of the small effect emerging in
the acute phase of the study. There was no significant change in overall neurocognition
between 8- and 52-weeks/termination. At the level of specific neuropsychological domains,
very small to small changes in several domain scores achieved statistical significance. These
included changes in the Fine Motor, Inhibitory Control, and Social Cognition domains
between baseline and week-8, and Fine Motor, Inhibitory Control, Attention, and Cognitive
Efficiency between baseline and week-52/termination. No significant changes were
observed in Short-Term Memory (which included measures of new learning), nor, as
expected, were changes observed in Full Scale IQ or the Academic Achievement composite
score at any time point. With the exception of greater improvements in attention from week
8 to termination in the older youth, age was not a significant predictor of neurocognitive
outcomes. In addition, although sample sizes are small, no differences among medication
groups on neurocognitive outcomes were observed. Lastly, neurocognitive change at any
time point was not reliably associated with baseline or change in diagnostic-clinical
symptoms.
Our findings are consistent with recent large studies of adults in documenting minimal
cognitive benefits with antipsychotic treatment.16, 17, 46 The small magnitude of the
performance improvements that emerged in this trial and others have been interpreted as
consistent with practice effects.16, 45, 47, 48 Moreover, given that treatment effects were
small and most likely to be observed in the acute phase, it is possible that practice and/or
placebo effects were responsible for the changes in neurocognitive performance that
emerged.47, 48 Practice effects cannot be ruled out in the present study due to the absence of
a control group. Several studies have estimated that practice effects are at least in the small
and often in the moderate range, including for tests similar to those used in TEOSS (e.g.,
MATRICS).49 Some clinical treatment study researchers have argued that when taking
confidence intervals into consideration, effect sizes for conclusively nonrandom changes
would have to be substantially higher.48
The absence of a reliable relationship between level of baseline clinical symptoms and
neurocognitive change is not surprising given the ample literature documenting negligible to
small relationships between clinical symptoms of schizophrenia and neurocognitive test
scores in adults.7, 50 Similar findings are also noted in studies examining the relationship
between cognitive change from baseline and changes in symptom measures.16 Nonetheless,
symptom reduction might be associated with better task engagement which may, in turn,
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significantly change performance on cognitive measures.50 Despite treatment with
antipsychotic medication, which substantially reduced clinical symptoms in approximately
half of the TEOSS youth,22 cognitive symptoms remain an area of ongoing vulnerability that
requires intervention and support across settings. At present, it appears that reducing
symptoms of psychosis with medication is not sufficient for remedying cognitive deficits.
However, it is reasonable to consider that by improving psychosis, antipsychotics might
mitigate some of the psychosis associated cognitive deficits and prevent further decline.
Previous speculation about the benefits of antipsychotic medication on neurocognition has
suggested that individuals with schizophrenia who are younger and closer to the onset of
their symptoms, may be more likely to benefit from the cognitive enhancing effects of
treatment.17,51 Unfortunately, our findings in this younger cohort do not support this
hypothesis and are comparable to adult studies that included older individuals with chronic
illness and more exposures to treatment and/or substances.
Others suggest that the cognitive enhancing effects of antipsychotic medication might be
realized in the context of adequate environmental and cognitive stimulation.52 The premise
is that just as muscle enhancing agents have little impact without exercise, so too might
antipsychotic medication require routine environmental, cognitive, and/or behavioral
stimulation to achieve a procognitive effect. In this vein, the majority of TEOSS subjects
were in school, including 45% who were receiving special education at the time of
enrollment. While TEOSS was not designed to track specific educational programming and
interventions, the fact that nearly all TEOSS subjects were receiving some form of
education-related cognitive stimulation tempers speculation that normative age-related
cognitive stimulation might interact with medication treatment to yield procognitive
benefits.
In addition to the absence of a control or placebo group, three limitations to the present
study also require consideration. First, the majority of TEOSS participants had prior
exposure to antipsychotics,22 thus raising the possibility that any potential cognitive
enhancing effects of antipsychotic medication may have already been achieved (e.g., carry-
over effects from prior medication treatments) and was represented in their initial, baseline
performance. Ethical concerns precluded a medication washout period and there was no
medication-free assessment of neurocognitive function. Secondly, as is common in
treatment studies, fewer patients contributed both baseline and follow-up neurocognitive
data leaving a significant minority (34%) who did not contribute data, thus limiting the
generalizability of the findings to patients treated with antipsychotics in the community.
Thirdly, we were unable to achieve the sample size and statistical power necessary to
conduct strong comparative tests of potential differential medication effects on cognition.
Low statistical power (which would allow detection of only large effects), however, limits
the value of null findings in this regard. At the same time, between group effects sizes were
negligible, and our findings complement recent large studies that have found no evidence of
differential beneficial effects of second-generation antipsychotics over first-generation
antipsychotics.
Youth in TEOSS demonstrated minimal neurocognitive improvement, and the
improvements observed were consistent with practice effects as described in adults with
chronic schizophrenia treated with first-generation antipsychotics and second-generation
antipsychotics. Improvements in cognitive symptoms are much more difficult to achieve
with either first-or second-generation antipsychotics than improvements in psychotic
symptoms. Moreover, despite earlier and less methodologically rigorous research suggesting
that second-generation antipsychotics provide broader clinical and cognitive benefit, TEOSS
and related adult studies indicate that antipsychotic treatment selection cannot be based on
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the presumption of a differential cognitive benefit of one medication over another.
Clinicians should not expect that all aspects of schizophrenia can be treated with a single
intervention, including antipsychotics. While it is reasonable to hypothesize that
antipsychotics might directly or indirectly mitigate psychosis-associated cognitive deficits,
their impact on cognition is not sufficient to remedy functional deficits associated with the
illness. Our findings underscore that treatment strategies other than antipsychotic medication
are required to improve the cognitive functioning of youth with EOS. Given that cognitive
deficits in EOS remain central, enduring, and functionally relevant, there remains a great
need for augmentative and multi-modal treatments targeting cognition. These include the
discovery of cognitive-enhancing agents and use of currently available psychosocial
interventions (e.g., cognitive remediation53 Cognitive Adaptation Therapy54 and supported
education interventions). Our data highlight the critical need for the development of
effective interventions for the durable cognitive deficits associated with schizophrenia,
particularly for youth with EOS given their cognitive and psychosocial at-risk status.
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Flow diagram of the progress through the Neurocognitive Battery phases of the Treatment of
Early-Onset Schizophrenia Spectrum Disorders Study (TEOSS).
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Table 1
Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Neurocognitive Domain and
Composite Scores
Name of Domain/Composite Measures
Domain Scores
1. Fine Motor Speed/Coordination 1. Finger Tapping, Grooved Pegboard- dominant and non-dominant hand performance
2. Attention 2. Auditory and visual VIGIL Continuous Performance Test (CPT) omission errors
3. Short-Term Memory 3. Hopkins Verbal Learning Test-Revised (HVLT-R) Total, Wide Range Assessment of Memory and
Learning (WRAML VL) Total, Visual Working Memory Test (VSWM) Mean Error 5-second delay,
Woodcock Johnson –III (WJ-III) Numbers Reversed Total
4. Cognitive Efficiency 4. Controlled Oral Word Association Test (COWAT) Letter and Semantic Fluency Total, Ruff
Figural Fluency Test (RFFT) Total Unique Designs
5. Inhibitory Control 5. Auditory and visual VIGIL: CPT commission errors
6. Social Cognition Eyes Test-Total Correct
Composite Scores
1. Academic Achievement 1. Wide Range Achievement Test (WRAT-3) Reading, Spelling, Arithmetic Standard Scores
2. Full Scale IQ 2. Four subtest Wechsler Abbreviated Scale of Intelligence (WASI)
3. Neurocognitive Composite Score 3. Unweighted average of Six Domain Scores: Fine Motor Speed/Coordination, Attention, Short-
Term Memory, Cognitive Efficiency, Inhibitory Control, and Social Cognition
Note: CPT = continuous performance test.
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Table 2
Baseline Demographic and Clinical Characteristics
Variable Neurocognitive Sample N=77 Non- Neurocognitive Sample N=39
 Age (years) – Mean (SD) 14.3 (2.4) 14.2 (2.3)
 Gender – % Male 66.2 61.5
 Race – % White 66.2 59.0
 Family incomea – Mean (SD) 2.9 (1.5) 2.6 (1.5)
 Handedness – % Right 86.8 86.7
 Special Education – % Yes 57.1 51.3
 Diagnosis – % Schizophrenia 66.2 64.1
 # prior psychiatric hospitalizations – Mean (SD) 0.7 (0.9) 0.9 (1.0)
 Age at first psychosis – Mean (SD) 11.0 (3.5) 11.3 (3.4)
 PANSS Total – Mean (SD) 104.4 (20.0) *94.9 (18.6)
 PANSS Positive – Mean (SD) 26.7 (5.6) 25.8 (6.1)
 PANSS Negative – Mean (SD) 26.2 (8.1) *22.6 (7.2)
 CGI Severity – Mean (SD) 5.7 (0.8) 5.4 (0.9)
 BPRS-C Total – Mean (SD) 44.5 (11.8) *39.8 (10.2)
Note: BPRS-C = Brief Psychiatric Scale for Children; CGI = Clinical Global Impression scale; PANSS = Positive and Negative Syndrome Scale.
a
Family income is described by the following categories: 1= <$20K, 2=$20K–<$40K, 3=$40K–<$60K, 4=$60K–<$80K, 5=$80K–<100K, and 6=
$100K+.
*
p<0.05 for test of difference in baseline measures between TEOSS neurocognitive and non-neurocognitive samples
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